Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Cholargos – page 54

1 033 clinical trials in Cholargos, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Cholargos at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Cholargos

Open in trial search

Thrombosis+1

Not recruiting

Study on the Effect of Tinzaparin Sodium on Survival in Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Tinzaparin Sodium
  • Sponsor:Institute Of Molecular Medicine And Biomedical Research

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Hidradenitis

Not recruiting

Study on the Effectiveness of AVTX-009 for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AVTX-009
  • Sponsor:Avalo Therapeutics Inc.

Neurodermatitis

Not recruiting

Study on the Effectiveness of Dupilumab Injections for Itch Relief in Adults with Lichen Simplex Chronicus

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dyslipidaemia

Not recruiting

Study Comparing Rosuvastatin and Fenofibrate with Pravastatin and Fenofibrate for Patients with Mixed Dyslipidemia at High Risk of Heart Disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Fenofibrate
  • Sponsor:Laboratoires S.M.B.

Plasma cell leukaemia

Not recruiting

Study on the Effectiveness and Safety of Bortezomib and Daratumumab for Patients with Primary Plasma Cell Leukemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Hellenic Society Of Hematology

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin with drug combination for newly diagnosed multiple myeloma patients who cannot receive transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Hellenic Society Of Hematology

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin combined with pomalidomide, dexamethasone, and daratumumab in patients with relapsed/refractory multiple myeloma who previously had 1-3 treatments and are lenalidomide resistant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Hellenic Society Of Hematology

Plasma cell myeloma

Not recruiting

Study of isatuximab with drug combination for newly diagnosed multiple myeloma patients with severe kidney problems

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Hellenic Society Of Hematology

Plasma cell myeloma

Not recruiting

Study on the Safety and Effects of Belantamab Mafodotin with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Hellenic Society Of Hematology

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Celltrion Inc.

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Cholargos

What the registry says about research in the country

01 Lung Cancer Research

Comprehensive studies evaluating novel treatments for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including investigations of targeted therapies and immunotherapy combinations.

  • Advanced treatment comparisons
  • Therapy combinations evaluation
  • Metastatic disease management

Research focuses on improving survival rates and treatment effectiveness for patients with various stages of lung cancer.

02 Breast Cancer Studies

Innovative clinical trials examining treatments for HER2-positive and estrogen receptor-positive breast cancer, with particular attention to early-stage and metastatic conditions.

  • Targeted therapeutic approaches
  • Hormone therapy evaluation
  • Recurrence prevention

Studies aim to enhance treatment outcomes and reduce recurrence risks in breast cancer patients.

03 Urological Cancers

Advanced research into bladder cancer and metastatic prostate cancer, exploring innovative combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Treatment resistance studies
  • Novel drug evaluations

Trials focus on improving treatment outcomes for patients with advanced urological malignancies.

04 Gastrointestinal Oncology

Studies investigating treatments for advanced colorectal cancer, particularly focusing on specific genetic mutations and targeted therapies.

  • Mutation-specific treatments
  • Combination therapy assessment
  • Advanced disease management

Research aims to develop personalized treatment approaches based on genetic profiles.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.